In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Synaptic Pharmaceutical Corp.

Division of H. Lundbeck AS
www.synapticcorp.com

Latest From Synaptic Pharmaceutical Corp.

Faust Pharmaceuticals

Strasbourg, France-based Faust Pharmaceuticals aims to identify and develop small molecule drug candidates that can modulate the level of neurotransmitters in the brain to treat neurodegenerative disorders including Parkinson's Disease and Alzheimer's Disease.
BioPharmaceutical

Faust Pharmaceuticals

Strasbourg, France-based Faust Pharmaceuticals aims to identify and develop small molecule drug candidates that can modulate the level of neurotransmitters in the brain to treat neurodegenerative disorders including Parkinson's Disease and Alzheimer's Disease.
BioPharmaceutical Europe

Medical Acquisitions: No Icebreaker in Sight

At the top of the industry, consolidation has frozen out much additional M&A; horizontal mergers among large companies have become much more difficult to get through regulatory authorities as the industries themselves have consolidated. In medical devices, M&A is at a 10-year low, reflecting a paucity of high-value small-company opportunities. Perhaps as important, some successful big-company development programs undermine a basic assumption of medical device investing: that big companies must source innovation from small ones, usually through acquisitions. Meanwhile In biotech, the number and value of M&A is down, despite the apparent logic of consolidation and the unprecedented willingness of sellers to accept low valuations. The key problem is that there are few buyers: those without extremely strong balance sheets aren't willing to take on additional burn rates, having seen some acquirers come to grief as their new, apparently stronger companies are unable to raise money in this bear market.
BioPharmaceutical Medical Device

Grunenthal Learns to Leverage

Grunenthal is reorganizing to become a better marketer, collaborator and innovator--a private firm that will thrive in the turbulent European market.
BioPharmaceutical North America
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • H. Lundbeck AS
  • Senior Management
  • Errol de Souza, PhD, Pres. & CEO
    Theresa A Banchek, PhD, VP, Research
    Robert L Weinshank, PhD, VP, Bus. Dev.
  • Contact Info
  • Synaptic Pharmaceutical Corp.
    Phone: (201) 261-1331
    215 College Rd.
    Paramus, NJ 07652
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register